| Literature DB >> 32341047 |
Harry Klimis1,2, Aravinda Thiagalingam3,2, Clara K Chow3,2.
Abstract
INTRODUCTION: Mobile health may be an effective means of delivering customised individually directed health promotion interventions for cardiovascular disease (CVD) primary prevention. The aim of this study is to evaluate the effectiveness of a lifestyle-focused text messaging programme for primary CVD prevention. METHODS AND ANALYSIS: Single-blind randomised controlled trial with 6 months' follow-up in 246 patients with moderate-high absolute cardiovascular risk and without coronary heart disease recruited from a rapid access cardiology clinic. Participants will be randomised to receive either usual care or TextMe2 (text message-based prevention programme). The TextMe2 programme provides support, motivation and education on five topics: diet, physical activity, smoking, general cardiovascular health and medication adherence, and is delivered in four text messages per week over 6 months. The primary outcome is change in the proportion of patients who have three or more of five key modifiable risk factors that are uncontrolled (low-density lipoprotein >2.0 mmol/L, systolic blood pressure >140 mm Hg, body mass index >24.9 kg/m2, physical activity (less than the equivalent of 150 min of moderate intensity each week), current smoker). Secondary outcomes are changes in single biomedical risk factors, behavioural risk factors, quality of life, depression/anxiety scores, medication adherence, cardiovascular health literacy and hospital readmissions/representations. Analysis will be according to the intention-to-treat principle and full statistical analysis plan developed prior to data lock. ETHICS AND DISSEMINATION: This study has been approved by the Western Sydney Local Health District Human Research Ethics Committee at Westmead (AU/RED/HREC/17/WMEAD/186). Results will be presented at scientific meetings and published in peer-reviewed publications. TRIAL REGISTRATION NUMBER: ACTRN12618001153202. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: cardiology; clinical trials; medical education & training; preventive medicine; protocols & guidelines; risk management
Mesh:
Year: 2020 PMID: 32341047 PMCID: PMC7204915 DOI: 10.1136/bmjopen-2020-036767
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Study design and flow. CAD, coronary artery disease; SMS, short messaging service.
Figure 2TextMe2 message bank development. CVD, cardiovascular disease; TEXT ME, Tobacco, Exercise and Diet Messages; TEXTMEDS, TEXT messages to improve MEDication adherence and Secondary prevention.
TextMe2 message modules
| Module 1 | General cardiovascular knowledge | 9 weblinks |
| Module 2a | Standard diet | 4 weblinks |
| Module 2b | Vegetarian diet | 4 weblinks |
| Module 3a | Capable of full physical activity | 7 weblinks |
| Module 3b | Non-weight-bearing activity only | 7 weblinks |
| Module 3c | Unable to exercise | 7 weblinks |
| Module 4a | Current smoker | 3 weblinks |
| Module 4b | Taking cardiometabolic medications | 2 weblinks |
| Module 4c | Non-smoker | 3 weblinks |
| Module 4d | Not taking cardiometabolic medications | 2 weblinks |
Primary and secondary outcomes
| Primary | Per cent change in the proportion of patients who have three or more out of five uncontrolled modifiable risk factors (LDL-C >2.0 mmol/L, systolic blood pressure >140 mm Hg, BMI >24.9, physical activity (less than the equivalent of 150 min of moderate intensity each week), current smoker) |
| Secondary | Fasting LDL-C Systolic blood pressure (average of two readings) BMI and waist circumference Change in HbA1c (for those with diabetes) Global Physical Activity Questionnaire (GPAQ) and time spent in different domains Self-reported smoking rate (cigarettes per day in last 7 days) and quit attempts (if relevant) Servings of vegetables and fruits consumed each day (self-report of portions consumed in last 7 days) Quality of life as assessed by the EQ-5D-5L Health Survey Depression score as assessed by Patient Health Questionnaire-9 (PHQ-9) Generalized Anxiety Disorder 7-item (GAD-7) score Cardiovascular health literacy Cardiometabolic medication adherence—self-reported Hospital readmissions/representations (self-report, medical records) |
BMI, body mass index; HbA1c, glycosylated haemoglobin; LDL-C, low-density lipoprotein-cholesterol.
Data collection
| Data collected | Assessment | Baseline | 6 months |
| Australian Absolute Cardiovascular Risk Score | Framingham risk equation optimised for an Australian population. | ||
| LDL-cholesterol, HDL-cholesterol, total cholesterol, triglycerides | Fasting blood sample. | ||
| Blood pressure | Average of two resting, sitting digital recordings. | ||
| Body measurements | Weight, height, waist circumference. | ||
| Presence or control of diabetes | HbA1c, fasting blood sugar level. | ||
| Smoking quantity, quit attempts | Self-report. | ||
| Medication adherence | Self-report of use over last 7 and 30 days. | ||
| Diet | Self-report of fruit and vegetable serving consumption over last 7 days. | ||
| Physical activity | Global Physical Activity Questionnaire (GPAQ). | ||
| Health literacy | BRIEF Health Literacy. | ||
| Cardiovascular health literacy | Cardiovascular knowledge survey. | ||
| Quality of life | EQ-5D-5L Health Survey. | ||
| Depressive symptoms | Patient Health Questionnaire-9 (PHQ-9). | ||
| Anxiety symptoms | Generalized Anxiety Disorder 7-item (GAD-7) score. | ||
| Cardiovascular events | Hospital admission with chest pain, congestive heart failure, non-fatal AMI, CV death. Self-report and hospital records. | ||
| Use of other health services | GP and specialist services, community services, allied health. Self-report. | ||
| Evaluation of text messages | Qualitative survey assessing text message suitability (intervention only). |
AMI, acute myocardial infarction; CV, cardiovascular; GP, general practitioner; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.